OptimizeRx Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OptimizeRx Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.43M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $92.13M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $71.52M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $62.45M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $61.29M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $43.31M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $24.60M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $21.21M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $12.13M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $7.75M | Mar 8, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.43M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $92.13M | Mar 12, 2026 |
| FY2022 | Dec 31, 2022 | $1.03M | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | $4.52M | Mar 10, 2023 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.43M | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $6.21M | Mar 8, 2018 |
| FY2012 | Dec 31, 2012 | $2.05M | Mar 12, 2013 |
| FY2012 | Dec 31, 2011 | $1.11M | Mar 12, 2013 |
| FY2011 | Dec 31, 2010 | $71.1K | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.60M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $59.38M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $42.90M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $38.97M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $35.64M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $24.11M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $15.44M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $12.21M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.95M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $4.34M | Mar 8, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.13M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($20.11M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($17.57M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($11.44M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $378.1K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.21M) | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | ($3.14M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $226.3K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($2.10M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($1.54M) | Mar 8, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($13.71M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($26.40M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($12.29M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $361.1K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($2.14M) | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | ($3.69M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $180.1K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($2.13M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($1.58M) | Mar 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2020 | Dec 31, 2020 | $0 | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $1.60M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Mar 26, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $33.49M | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | $27.70M | Mar 10, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.72M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.89M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($7.24M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.65M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $726.0K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($6.31M) | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | ($1.66M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $792.6K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($1.48M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($466.0K) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $112.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $87.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $81.0K | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $100.3K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $68.0K | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $87.7K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $34.4K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $42.2K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $178.4K | Mar 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $176.92M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $171.17M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $183.37M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $134.65M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $140.99M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $60.33M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $56.64M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $25.05M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $9.76M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $11.48M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.62M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $54.17M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $56.82M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $8.54M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $9.61M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $10.35M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $11.78M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $6.60M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $3.54M | Mar 12, 2019 |
| FY2011 | Dec 31, 2011 | $1.30M | Mar 30, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.29M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $117.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $126.55M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $126.11M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $131.38M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $49.97M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $44.86M | Mar 10, 2023 |
| FY2020 | Dec 31, 2018 | $18.46M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $6.22M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $7.81M | Mar 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.87M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $70.87M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $78.36M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $22.67M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $14.74M | Apr 15, 2024 |
| FY2022 | Dec 31, 2020 | $14.74M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $14.74M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.68M | Mar 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($79.24M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($84.37M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($64.26M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($46.69M) | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | ($35.25M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($35.63M) | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | ($33.42M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($30.28M) | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($30.36M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($28.26M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.37M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $13.38M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $13.85M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $18.21M | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | $84.68M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $10.52M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | $18.85M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $8.91M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $5.12M | Mar 26, 2020 |
| FY2018 | Dec 31, 2016 | $7.03M | Mar 12, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.29M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $34.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $38.29M | Mar 20, 2025 |
| FY2011 | Dec 31, 2011 | $0 | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | $1.00M | Mar 30, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Mar 8, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 12, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.76M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 18.45M | Mar 12, 2026 |
| FY2022 | Dec 31, 2022 | 18.29M | Mar 10, 2023 |
| FY2022 | Dec 31, 2021 | 17.86M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 15.22M | Mar 10, 2023 |
| FY2020 | Dec 31, 2019 | 14.61M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 12.04M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 9.77M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 29.72M | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | 29.03M | Mar 8, 2017 |